Gustavo Viani: Prostate SBRT with an integrated focal boost demonstrated excellent 5-year outcomes
Gustavo Viani shared a post on LinkedIn:
“Prostate SBRT with an integrated focal boost demonstrated excellent 5-year outcomes
-Study Overview:
The hypo-FLAME trial explored a novel approach for treating intermediate- and high-risk prostate cancer using ultra-hypofractionated SBRT combined with a focal boost to the tumor.
-Treatment Details:
• received 35 Gy in 5 weekly sessions to the whole prostate
• An additional integrated focal boost of up to 50 Gy targeted the tumor based on MRI imaging
• Dose constraints for surrounding healthy tissues were prioritized to side effects
– Results:
• 5-Year Biochemical Disease-Free Survival (bDFS): 93% (CI 86%-97%)
• Toxicity Rates at 5 Years:
• Grade 2+ GU toxicity: 12%
• Grade 2+ GI toxicity: 4%.”
Authors: Karin Haustermans, Floris J. Pos, Uulke A. van der Heide, Lisa De Cock, Jochem van der Voort van Zyp, Hans De Boer, Robert J. Smeenk, Martina Kunze-Busch, Evelyn M. Monninkhof, Robin De Roover, Sofie Isebaert and Linda G.W. Kerkmeijer.
Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023